Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: J Pain Symptom Manage. 2016 Jul 9;52(4):459–468.e1. doi: 10.1016/j.jpainsymman.2016.05.013

Table 1.

Baseline patient characteristics

FPNS
N=12 (%)a
Placebo
N=12 (%)a
All patients
N=24 (%)a
Average age (range) 51.5 (44.7, 58.3) 53.3 (45.0, 61.6) 52.4 (47.5, 57.4)
Female sex 9 (75.0) 4 (33.3) 13 (54.2)
Race
    Caucasian 8 (66.7) 8 (66.7) 16 (66.7)
    Black 3 (25) 2 (16.7) 5 (20.8)
    Hispanic 1 (8.3) 2 (16.7) 3 (12.5)
Education
    High school or less 4 (33.3) 2 (16.7) 6 (25.0)
    College 8 (66.7) 7 (58.3) 15 (62.5)
    Advanced degree 0 3 (25.0) 3 (12.5)
Cancer type
    Breast 3 (25.0) 2 (16.7) 5 (20.8)
    Gastrointestinal 2 (16.7) 4 (33.3) 6 (25.0)
    Genitourinary 2 (16.7) 0 2 (8.3)
    Gynecologic 2 (16.7) 0 2 (8.3)
    Lung 1 (8.3) 2 (16.7) 3 (12.5)
    Hematologic 0 2 (16.7) 2 (8.3)
  Others 2 (16.7) 2 (16.7) 4 (16.7)
Cancer stage
    Metastatic/refractory 8 (66.7) 10 (83.4) 18 (75.0)
    Localized/Locally advanced 4 (33.3) 2 (16.6) 6 (25.0)
*Cancer Dyspnea Scale, mean (SD)
    Effort 6.3 (3.7) 4.6 (2.7) 5.5 (3.3)
    Anxiety 3.6 (3.0) 2.3 (3.7) 3.0 (3.4)
    Discomfort 2.8 (1.5) 2.4 (1.4) 2.6 (1.4)
    Total 12.8 (7.1) 9.3 (5.8) 11.1 (6.6)
Average dyspnea NRS during
breakthrough episodes over the last
week, mean (SD)
4.4 (1.4) 4 (1.0) 4.2 (1.2)
Co-morbidities
    COPD 2 (16.7) 2 (16.7) 4 (16.7)
    Heart failure 1 (8.3) 0 1 (4.2)
    Asthma 5 (41.7) 0 5 (20.8)
    Bronchiectasis 0 0 0
Concurrent therapies
    Opioids 12 (100.0) 12 (100.0) 24 (100.0)
    Bronchodilators 6 (50.0) 5 (41.7) 11 (45.8)
    Steroids 0 0 0
    Supplemental oxygen 1 (8.3) 1 (8.3) 2 (8.3)
Morphine equivalent daily doses,
median (interquartile range) in mg
137.5 (125, 200) 175 (135, 325) 158 (133, 235)
Karnofsky performance status, mean
(SD)
75.8 (9.0) 75.8 (10.8) 75.8 (9.7)

Abbreviations: COPD, chronic obstructive pulmonary disease; NRS, numeric rating scale; SD, standard deviation

a

unless otherwise specified